Welcome to our dedicated page for LakeShore Biopharma Co. news (Ticker: LSB), a resource for investors and traders seeking the latest updates and insights on LakeShore Biopharma Co. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LakeShore Biopharma Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LakeShore Biopharma Co.'s position in the market.
LakeShore Biopharma (LSB) reported strong financial results for H1 FY2025, achieving total revenue of RMB 371.9 million, up 36.2% YoY. The company posted its first net income since 2013 at RMB 20.6 million, compared to a net loss of RMB 174.5 million in the same period last year. Gross profit increased by 39.1% to RMB 307.3 million, with improved margins at 82.6%.
Operating expenses decreased by 31.6% to RMB 276.4 million, driven by cost reduction initiatives and completion of COVID-19 vaccine trials. The company received NMPA approval for a Phase III trial of its YSJA rabies vaccine's simplified regimen. For FY2025, LSB projects revenues between RMB 665-700 million (16-22% YoY growth) and Adjusted EBITDA of RMB 76-89 million.
LakeShore Biopharma (Nasdaq: LSB) announced that the Shenyang Municipal Public Security Bureau has initiated criminal investigations into former chairman Yi Zhang for alleged misappropriation of corporate assets and company mismanagement. Zhang was removed from all executive positions by March 2024, but subsequently used the Company's Seal to forge contracts and falsify debts, leading to asset freezes at subsidiary Liaoning Yisheng Biopharma.
The Bureau has gathered sufficient evidence of criminal conduct and is initiating procedures for an international arrest warrant as Zhang has fled China. Despite these challenges, the company maintains strong market position as second in China's Rabies vaccine market and has reaffirmed its financial guidance through FY2025. Management has secured additional financing to maintain operations and is pursuing legal action for shareholder compensation.
LakeShore Biopharma (Nasdaq: LSB) has initiated a Biologics License Application to Pakistan's Drug Regulatory Authority for its PIKA rabies vaccine. The application is supported by successful pivotal trial results showing the vaccine's ability to provide accelerated protection in a one-week regimen, compared to conventional three- or four-week regimens. The Phase 3 trial involved 4,500 participants from the Philippines and Pakistan, demonstrating superior immunogenicity and safety. Pakistan, among the top five countries for human rabies cases, reports over 1.5 million dog bites and 2,000-5,000 human deaths annually. The vaccine, which received FDA orphan drug designation, utilizes proprietary PIKA adjuvant technology to produce stronger immune responses.
LakeShore Biopharma (Nasdaq: LSB) has announced regaining compliance with Nasdaq's minimum bid price requirement. The company received a compliance notice on October 21, 2024, confirming that its ordinary shares maintained a closing bid price of $1.00 or higher for 11 consecutive business days from October 4-18, 2024. This resolves the non-compliance notice issued on October 24, 2023, when the company's shares traded below $1.00 for 30 consecutive business days. LakeShore Biopharma, formerly YS Biopharma, develops vaccines and therapeutic biologics for infectious diseases and cancer using its PIKA® immunomodulating technology platform.
LakeShore Biopharma (Nasdaq: LSB) has received NMPA approval for a Phase III clinical trial to evaluate simplified four-dose regimens of its YSJA rabies vaccine. The trial will compare two alternative schedules: the Zagreb Regimen (2-1-1) and Modified Essen Regimen (1-1-1-1) against the conventional five-dose Essen regimen (1-1-1-1-1). The study, set to begin in December 2024, aims to improve patient adherence, reduce hospital visits, and decrease costs while maintaining comparable immunogenicity. The YSJA vaccine has already sold over 100M doses since market approval.
LakeShore Biopharma (Nasdaq: LSB) has provided financial guidance for the first half of fiscal year 2025 and reaffirmed its full-year guidance, highlighting strong execution and positive business momentum. The company anticipates double-digit year-over-year revenue growth for FY2025 and expects to achieve breakeven during this period. Preliminary total revenue for the first six months is estimated between RMB350 million to RMB380 million, representing a 28% to 39% growth from the same period in FY2024.
LakeShore Biopharma is pursuing strategic initiatives including cost reductions, organizational restructuring, and management process enhancements to boost operational efficiency. The company is also focused on driving future growth through strategic alliances, product licensing, asset purchases, partnerships, and co-promotion deals. CEO Xu Wang expressed confidence in maintaining positive momentum and achieving financial and operational objectives, noting the company's second position in China's Rabies vaccine market and its commitment to enhancing sustainability, efficiency, and innovation.
LakeShore Biopharma Co., (Nasdaq: LSB) announced the results of its extraordinary general meeting (EGM) held on September 27, 2024. Shareholders approved a 10-for-1 share consolidation effective October 1, 2024, to regain compliance with Nasdaq's minimum bid price requirement. The consolidation will change the company's authorized share capital from 2,500,000,000 ordinary shares at US$0.00002 par value to 250,000,000 ordinary shares at US$0.0002 par value.
The company's ordinary shares will trade on a split-adjusted basis starting October 4, 2024. Shareholders' percentage ownership and voting power will remain largely unchanged, except for minor adjustments due to fractional shares being rounded up. The stock will continue trading on Nasdaq under the symbol LSB.
LakeShore Biopharma (Nasdaq: LSB) has announced an extraordinary general meeting (EGM) of shareholders on September 27, 2024, to be held virtually via Zoom. The primary purpose is to approve resolutions aimed at regaining compliance with Nasdaq's minimum bid price requirement before October 21, 2024. Key proposals include:
1. A 10-to-1 share consolidation effective October 1, 2024
2. Amending and restating the company's memorandum and articles of association
The record date for shareholder participation is set for September 11, 2024. The board of directors fully supports these resolutions and recommends shareholders vote in favor.
LakeShore Biopharma (Nasdaq: LSB) has announced significant leadership transitions effective September 1, 2024. Xu Wang, previously Chief Operation Officer, has been appointed as the new Chief Executive Officer, succeeding Dave Chenn and Dr. Hui Shao. Dr. Shao transitions to the role of Chief Business Officer, focusing on global strategic planning and transactions. Additionally, he has been appointed as Vice Chairman of the Board.
Rachel Yu, formerly Interim Chief Financial Officer, has been promoted to Chief Financial Officer. She also maintains her role as a partner at Oceanpine Capital's healthcare practice. Xu Wang joins the company's Board of Directors as a new member. These changes aim to strengthen LakeShore Biopharma's leadership team as it continues its mission in developing vaccines and therapeutic biologics for infectious diseases and cancer.
LakeShore Biopharma (Nasdaq: LSB) announced financial results for Fiscal Year 2024, ending March 31, 2024. Despite revenue challenges due to supply chain issues, the company reported:
- Revenue of RMB573.4 million (US$80.8 million), down 16.6% year-over-year
- Gross profit of RMB455.7 million (US$64.2 million)
- Gross margin increased to 79.5%, up 1.8 percentage points
- Net loss of RMB433.5 million (US$61.1 million)
LakeShore Biopharma maintains its position as a leading rabies vaccine producer in China, having sold over 27.3 million doses since October 2020. The company's pipeline continues to advance, with positive interim results from the PIKA rabies vaccine Phase III trial. For Fiscal Year 2025, LakeShore anticipates double-digit revenue growth and expects to achieve breakeven.
FAQ
What is the current stock price of LakeShore Biopharma Co. (LSB)?
What is the market cap of LakeShore Biopharma Co. (LSB)?
